"Arformoterol"

Arformoterol An official website of the United States government Here's how you know Log inAccess keysNCBI HomepageMyNCBI HomepageMain ContentMain NavigationBookshelfSearch databaseBooksAll DatabasesAssemblyBiocollectionsBioProjectBioSampleBooksClinVarConserved DomainsdbGaPdbVarGeneGenomeGEO DataSetsGEO ProfilesGTRHomoloGeneIdentical Protein GroupsMedGenMeSHNLM and EffectsSummary of Use during LactationArformoterol is the R-enantiomer of the long-acting beta-2 adrenergic agonist, formoterol. Although no published data exist on the use of arformoterol by inhalation during lactation, data from the related drug, terbutaline, indicate that very little is expected to be excreted into breastmilk.[1] The authors of several reviews and an expert panel agree that use of inhaled

Predictors of Nebulized Arformoterol Treatment: A Retrospective Analysis of Medicare Beneficiaries with Chronic Obstructive Pulmonary Disease. This study examined sociodemographic and clinical characteristics, treatment patterns, and health resource utilization among Medicare beneficiaries with chronic obstructive pulmonary disease (COPD) to identify predictors of nebulized arformoterol treatment. Using Medicare administrative data from 2010 to 2014, beneficiaries with ≥2 COPD outpatient visits ≥30 d apart or ≥1 COPD-related hospitalization(s) (ICD-9-CM 491.xx, 492.xx, and 496) were identified. Inclusion criteria required ≥1 COPD medication claim(s) and continuous enrollment in Parts A, B, and D. Four cohorts were identified: (a) 11,887 arformoterol users, (b) a subsample of arformoterol

Long-term health-related quality-of-life and symptom response profiles with arformoterol in COPD: results from a 52-week trial Symptom severity is the largest factor in determining subjective health in COPD. Symptoms (eg, chronic cough, dyspnea) are associated with decreased health-related quality of life (HRQoL). We evaluated the impact of arformoterol on HRQoL in COPD patients, measured by St George's Respiratory Questionnaire (SGRQ). Post hoc growth mixture model (GMM) analysis examined symptom response profiles. We examined data from a randomized, double-blind, parallel-group, 12-month safety trial of twice-daily nebulized arformoterol 15 µg (n=420) versus placebo (n=421). COPD severity was assessed by Global Initiative for Chronic Obstructive Lung Disease (GOLD) status. GMM analysis

Health resource utilization for inpatients with COPD treated with nebulized arformoterol or nebulized formoterol Arformoterol is the (R,R)-enantiomer of formoterol. Preclinical studies suggest that it is a stronger bronchodilator than the racemic (R,R/S,S)-formoterol; however, its potential clinical advantages have not been demonstrated. This study compared the length of stay (LOS), 30-day readmission rates, and doses of rescue medication administered in hospitalized patients with COPD who were treated with nebulized arformoterol or nebulized formoterol. This retrospective analysis utilized data from Premier, Inc. (Charlotte, NC, USA), the largest nationwide hospital-based administrative database. COPD patients ≥40 years of age were included if they were hospitalized between January 2011

Health Status of Patients with Moderate to Severe COPD after Treatment with Nebulized Arformoterol Tartrate or Placebo for 1 Year. Chronic obstructive pulmonary disease (COPD) is a progressive disease that impairs both objectively measured lung function and patient-reported health status. In a randomized clinical trial of patients with moderate to severe COPD, we compared changes in health status after adding arformoterol tartrate or placebo to patients' treatment regimens. In this multicenter, double-blind trial, patients were randomized to receive nebulized arformoterol 15 µg BID (n = 420) or matched placebo (n = 421). Treatment with other COPD medications was permitted, except for long-acting β-agonists. Inclusion criteria were a forced expiratory volume in 1 second (FEV) ≤65

One-year safety and efficacy study of arformoterol tartrate in patients with moderate to severe COPD. Arformoterol tartrate (arformoterol, 15 μg bid) is a nebulized long-acting β2-agonist approved for maintenance treatment of COPD. This was a multicenter, double-blind, randomized, placebo-controlled study. Patients (aged ≥ 40 years with baseline FEV1 ≤ 65% predicted, FEV1 > 0.50 L, FEV1/FVC ≤ 70 %, and ≥ 15 pack-year smoking history) received arformoterol (n = 420) or placebo (n = 421) for 1 year. The primary assessment was time from randomization to respiratory death or first COPD exacerbation-related hospitalization. Among 841 patients randomized, 103 had ≥ 1 primary event (9.5% vs 15.0%, for arformoterol vs placebo, respectively). Patients who discontinued treatment for any reason (39.3% vs 49.9

Arformoterol/Budesonide for COVID-19 This is a multi-center, randomized, double-blind, placebo-controlled, parallel, phase 2 study to evaluate the efficacy and safety of UI030 in COVID-19 patients Patients with moderate and severe COVID-19 were randomly assigned (1:1) to receive either UI030 (Budesonide/Arformoterol dry powder inhaler, 2 inhalations b.i.d) or placebo for 2 weeks.

licensed for COPD: formoterol, arformoterol and salmeterol.ObjectiveTo determine the clinical efficacy of inhaled formoterol, arformoterol and salmeterol as compared to placebo for chronic maintenance treatment in adult patients with COPD. Since COPD causes important morbidity and mor-tality, we rank these outcomes as most important. Another potential benefit of inhaled LABA would be meaningful improvement in disabling symptoms of COPD.MethodsInclusion criteria: randomized placebo controlled parallel group clinical trials (RCTs) with clinically important out-comes. We used standard Cochrane methods for search strategy, data collection and analysis.1ResultsSince arformoterol is an R-R enantiomer of racemic formoterol, we combined their analyses. We identified 22

, as described in Table A. Table A. Drugs included in the review Class Drugs ICS Beclomethasone,a budesonide,a ciclesonide,a Flunisolide,a fluticasone,a mometasone,a triamcinoloneb LABA Arformoterol, formoterol,a olodaterol, salmeterol,a vilanterol,a,c LAMA Aclidinium, glycopyrrolate, tiotropium,a umeclidinium FDA = Food and Drug Administration; ICS = inhaled corticosteroid; LABA = long-acting β2-agonist

SubstancePubMedSimilar articles in PubMedReview Metaproterenol.[Drugs and Lactation Database (...]Review Arformoterol.[Drugs and Lactation Database (...]Review Salmeterol.[Drugs and Lactation Database (...]Review Pirbuterol.[Drugs and Lactation Database (...]Review Bitolterol.[Drugs and Lactation Database (...]See reviews...See all...Recent ActivityClearTurn OffFormoterol - Drugs and Lactation Database (LactMed®)See

Database (LactMed) - Record FormatLactMed - Database Creation and Peer Review ProcessFact Sheet. Drugs and Lactation Database (LactMed)Drugs and Lactation Database (LactMed) - GlossaryLactMed Selected ReferencesDrugs and Lactation Database (LactMed) - About Dietary SupplementsBreastfeeding LinksRelated informationPMCPubChem SubstancePubMedSimilar articles in PubMedReview Arformoterol.[Drugs and Lactation

informationPubChem SubstanceSimilar articles in PubMedReview Umeclidinium.[Drugs and Lactation Database (...]Review Montelukast.[Drugs and Lactation Database (...]Compatible Stability and Aerosol Characteristics of Atrovent(®) (Ipratropium Bromide) Mixed with Salbutamol Sulfate, Terbutaline Sulfate, Budesonide, and Acetylcysteine.[Pharmaceutics. 2020]Review Arformoterol.[Drugs and Lactation Database

Aerolizer Perforomist Arformoterol tartrate Brovana